Beyond CAR-T: Synthetic Immune Receptor T (SIR-T™) cells for solid tumors

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Beyond CAR-T: Synthetic Immune Receptor T (SIR-T™) cells for solid tumors

This webinar explores how synthetic immune receptor T cells (SIR-T™) are being engineered to better replicate natural T cell signaling and improve activity in challenging solid tumor environments, including metastatic castration-resistant prostate cancer.

Drawing on 12 years of preclinical research, the session will present the receptor design strategy used to evaluate thousands of prototypes and identify a lead candidate. Attendees will gain insight into the IND-enabling roadmap, early comparative efficacy data versus CAR-T models, and the strategy for expanding the platform to additional cancers such as melanoma and kidney cancer.

Join this webinar to:

Examine structural differences between SIR-T™ and CAR-T architectures, specifically how SIR-T™ better mimics natural T-cell signaling
Review preclinical data comparing tumor reduction and survival outcomes in SIR-T™ versus traditional CAR-T models
Understand the multi-prototype screening framework used by USC to evaluate thousands of receptor designs over an 12-year development program
Gain practical insight into the preclinical and regulatory steps required to advance an academic “homegrown” cell therapy toward IND submission and first-in-human trials

Register now to gain practical insight into receptor engineering strategies, preclinical development frameworks, and translational considerations shaping new cell therapy approaches for solid tumors.

Preet Chaudhary, MD, PhD

Professor of Medicine at Keck School of Medicine of USC and Founder of Angeles Therapeutics, Inc

Preet M. Chaudhary is Professor of Medicine, Bloom Family Chair in Lymphoma Research, Chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of USC and Director of the USC Norris Blood and Marrow Transplant and Cell Therapy Program. He is also the founder of Angeles Therapeutics, Inc. His research focuses on developing cellular immunotherapies, including next generation CAR-T/NK platforms, such as the synthetic immune receptor (SIR-T™) platform, for hematologic malignancies, solid tumors and autoimmune disorders.

You have registered for this webinar